In a decision that could fundamentally reshape the fight against HIV, the US Food and Drug Administration (FDA) has given its approval to Gilead Sciences’ lenacapavir, a groundbreaking twice-yearly injection for preventing HIV infection in adults and adolescents. Marketed under the brand name Yeztugo in the US, this innovative drug has been eagerly anticipated by both investors and HIV/AIDS activists…